Sponsors (4)
Expands and prioritizes sanctions/reporting against PRC‑linked fentanyl supply chains, lowers sanction thresholds to single significant acts/transactions, and requires new reports and briefings.
Official title: Modify the information about countries exporting methamphetamine that is included in the annual International Narcotics Control Strategy Report, to require a report to Congress on the seizure and production of certain illicit drugs, to impose sanctions with respect to the production and trafficking into the United States, of synthetic opioids, and for other purposes.
Introduced March 5, 2025 by James Risch · Last progress March 5, 2025
The bill strengthens U.S. tools and reporting to disrupt fentanyl and meth supply chains—especially those linked to the PRC—giving law enforcement faster sanctions and more focused intelligence at the cost of increased diplomatic tension, economic and compliance burdens for businesses, potential legal ambiguity, and higher administrative obligations.
Law enforcement and border communities will receive a coordinated, time-bound assessment and plan to disrupt fentanyl precursor supply chains linked to the PRC, improving targeting and multilateral cooperation to reduce illicit opioid flows.
Federal policymakers and enforcement agencies will have expanded and faster authorities (including sanctions for single significant transactions and targets that facilitate trafficking) to freeze assets and disrupt international financiers and suppliers of illicit opioids.
Congress, the President, and federal report drafters will get clearer, more specific, and more timely reporting on PRC-linked actors and major methamphetamine source countries, with new deadlines and definitions to focus oversight and diplomatic engagement.
U.S. taxpayers and policymakers may face increased diplomatic friction with the PRC and other countries because the bill prioritizes and publicly singles out Chinese-linked actors and identifies foreign source countries, risking retaliation or strained cooperation.
U.S. businesses, banks, and financial institutions will face higher risk of transaction disruption, sudden asset freezes, and compliance burdens that could disrupt trade and raise costs for consumers and companies.
Federal agencies, Congress, and stakeholders could encounter legal ambiguity and reduced transparency because broaded/altered chemical language and increased classified annexes limit clarity about covered substances and restrict public oversight.
Based on analysis of 7 sections of legislative text.
Changes U.S. reporting and sanction rules to target fentanyl and synthetic-opioid supply chains, with a focus on actors tied to the People’s Republic of China. It delays one annual foreign‑policy report date, requires new unclassified and classified assessments and briefings on PRC cooperation and precursor controls, expands the legal bases for imposing sanctions (including on financial facilitators and government entities), and adds reporting requirements on methamphetamine source countries. The bill broadens who can be sanctioned for fentanyl-related activity (including single large transactions, money-proceeds recipients, and entities that provide financial or material support), allows sanctions on foreign government entities and senior officials, and mandates prioritized identification of PRC persons involved in shipments to Mexico and other countries supplying fentanyl to the U.S.